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Abstract
Background: Hepatitis B infection (HBV) is a major Public Health Problem.
Perinatal transmission can be prevented with the identification of HBsAg(+) women and
administration of immunoprophylaxis to their newborns. A national prevention programme for
HBV with universal screening of pregnant women and vaccination of infants is in effect since 1998
in Greece.
Methods: To evaluate adherence to the national guidelines, all women delivering in Greece
between 17–30/03/03 were included in the study. Trained health professionals completed a
questionnaire on demographic data, prenatal or perinatal screening for HBsAg and the
implementation of appropriate immunoprophylaxis.
Results: During the study period 3,760 women delivered. Prenatal screening for HBsAg was
documented in 91.3%. Greek women were more likely to have had prenatal testing. HBsAg
prevalence was 2.89% (95%CI 2.3–3.4%). Higher prevalence of HBV-infection was noted in
immigrant women, especially those born in Albania (9.8%). Other risk factors associated with
maternal HBsAg (+) included young maternal age and absence of prenatal testing. No prenatal or
perinatal HBsAg testing was performed in 3.2% women. Delivering in public hospital and illiteracy
were identifiable risk factors for never being tested. All newborns of identified HBsAg (+) mothers
received appropriate immunoprophylaxis.
Conclusion: The prevalence of HBsAg in Greek pregnant women is low and comparable to other
European countries. However, immigrant women composing almost 20% of our childbearing
population, have significant higher prevalence rates. There are still women who never get tested.
Universal vaccination against HBV at birth and reinforcement of perinatal testing of all women not
prenatally tested should be discussed with Public Health Authorities.
Published: 09 May 2006
BMC Infectious Diseases 2006, 6:84 doi:10.1186/1471-2334-6-84
Received: 08 December 2005
Accepted: 09 May 2006
This article is available from: http://www.biomedcentral.com/1471-2334/6/84
© 2006 Papaevangelou et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2006, 6:84 http://www.biomedcentral.com/1471-2334/6/84
Page 2 of 6
(page number not for citation purposes)
Background
Hepatitis B infection (HBV) is a major Public Health
Problem. It is estimated that more than 350 million peo-
ple are chronic HBV carriers worldwide. About one forth
of them will develop chronic hepatitis and cirrhosis and
could develop hepatocellular carcinoma eventually [1].
The probability of becoming a chronic carrier is inversely
related to age at the time of infection [2,3]. Although only
5–10% of adults infected with HBV will become chronic
carriers, neonatal infection almost always leads to a
chronic carrier state (90%) whereas 30–60% of children
infected during the first five years of life will become
chronic HBV carriers [4]. The precise mechanism of this
has not yet been defined but it has been attributed to the
immaturity of the immune system of newborns and
young children and their inability to mount an effective
CTL response against HBV infection[5,6]. Acute and
chronic HBV infections are usually asymptomatic during
childhood. Up to 25% of infants and older children who
acquire chronic HBV infection will eventually develop
HBV-related hepatocellular carcinoma or cirrhosis [7].
The risk of perinatal transmission of HBV is 70% – 90%
for infants born to mothers who are HBsAg and HBeAg
positive, but it decreases to 5% – 20% for infants born to
anti-HBe positive mothers [2]. Children of HBV-infected
mothers remain at high risk of acquiring HBV infection by
person-to-person (horizontal) transmission during the
first 5 years of life [8].
More than 90% of the perinatal HBV infections can be
prevented with the identification of HBsAg-positive preg-
nant women so that their newborns can receive hepatitis
B vaccine and hepatitis B immune globulin (HBIG) soon
after birth [9,10]. If a woman delivering has an unknown
HBsAg status, the first dose of hepatitis B vaccine should
be administered to the newborn as soon as possible. If this
mother is found HBsAg(+) or her status remains
unknown, HBIG should be administered within the first
week of life[2]. Worldwide, it has also been recommended
that hepatitis B vaccine should be integrated into routine
vaccination schedules for infants, usually as a part of the
World Health Organization's Expanded Programme on
Immunization, especially in populations in which HBV
infection is acquired during childhood [11,12].
In Greece, selective vaccination of high-risk groups was
initiated in 1982. A national prevention programme for
hepatitis B with universal screening of pregnant women
and universal vaccination of infants and adolescents is in
effect since 1.1.98. It is recommended that all infants are
vaccinated for hepatitis B, however, birth dose of hepatitis
B vaccine is administered only to newborns of HBsAg-pos-
itive mothers.
According to recent seroepidemiologic studies among
army recruits [13] and blood donors[14] the prevalence of
HBV carriers is below 1% making therefore Greece a coun-
try of low endimicity. On the other hand however, the
influx of refugees from countries with higher endimicity
(Eastern Europe and other Balkan countries, mainly Alba-
nia) pose the threat of increasing incidence of chronic
HBV infection among people residing in Greece. In a
recent prospective study in a large Maternity Hospital in
Athens, the prevalence of HBsAg positivity was 2,8%.
Only 63.1% of women had been tested during prenatal
care. Moreover, risk factors associated with HBV carrier
state included residence in a rural area, being an immi-
grant or young < 25 y.o) [15].
The aim of this study is to assess whether guidelines for
the prevention of perinatal HBV infection are followed
properly in Greece in both national and regional level five
years after their implementation.
Methods
Surveillance of the adherence to the guidelines for the 
prevention of perinatal HBV infection
All pregnant women delivering in Greece between 17/03/
03 and 31/03/03 were included in this observational
study. All obstetric clinics of the country in public, private
and University Hospitals were included in the study. After
getting permission from the ethics committee and Public
Health Department of the Ministry of Health we con-
tacted by mail all Clinic Directors. Each clinic appointed
one contact person for the study. In most instances, the
head midwife responsible for the delivery room was the
contact person for the study. She was responsible for com-
pleting an anonymous questionnaire for every woman
delivering, which included demographic data (age, origin,
educational level and address) as well as data on prenatal
care and more specifically on prenatal screening for
HBsAg (if she had documented screening during prenatal
care, when, where and whether the result was known).
Furthermore, if prenatal screening for HBsAg was not doc-
umented, we noted whether examination of the HBsAg
serostatus (serology testing by ELISA) of the pregnant
woman upon admission to the delivery room was ordered
and whether appropriate immunoprophylaxis (intramus-
cular administration of the first dose of hepatitis B vaccine
and 0,5 ml HBIG simulataneously but at a different site
within 12–24 hours of life) was given to the newborn. To
reinforce compliance to the study, frequent telephone
calls to all contact persons were made and visits to differ-
ent regions of Greece were performed during the two
weeks of the study.
Statistical analysis
A database was created in EPI-Info2002 (Epidemiological
software of the Center for Diseases Control) and all dataBMC Infectious Diseases 2006, 6:84 http://www.biomedcentral.com/1471-2334/6/84
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recruited from the questionnaires were transferred to that
database in order to be analyzed. Data analysis was per-
formed using EPI-Info 2002 and SPSS. Total prevalence of
HBsAg(+) was calculated by adding women diagnosed
during prenatal screening and those diagnosed for the first
time in the delivery room (perinatally). Specific preva-
lence was calculated in each group of mothers. Chi-square
test was used to compare qualitative values, whereas for
quantitative values Students' t-test or non-parametric
Mann-Whitney/Wilcoxon test were used whenever appro-
priate.
Results
Most obstetric clinics agreed to participate in this study
(137/138). During the study period (17–30/03/03) 3,760
questionnaires were completed.
Most women were of Greek origin (79.97%), 10.88%
were born in Albania, 2.28% were of gipsy origin whereas
6.86% of women were immigrants from different coun-
tries. Women were almost equally distributed between
public (46.7%) and private (53.3%) clinics. Interestingly,
1677 (44.6%) of women from all over Greece, delivered
in Athens.
The prevalence of HBsAg(+) women delivering in Greece
during the study period was 2.89% (95%CI 2.3–3.4%) of
all tested. Women of Greek origin had significant lower
prevalence of HBsAg(+) 1.7% (95%CI 1.3–2.3%) com-
pare to Albanian women 9.8%, (95%CI 7.1–13.3%),
immigrants from other countries 5.7% (95%CI 2.9–
9.0%) and women of gipsy origin 3.6% (95%CI 0.8–
10.2) Table (1).
Prenatal screening for the presence of HBsAg was docu-
mented in 91.3% of women. In few women it was not
clearly documented in the questionnaire whether test
results were obtained prenatally or perinatally and those
could not be included in this analysis of prenatal screen-
ing. Greek women were more likely to have had prenatal
screening compare to non-Greek women Table (1).
Women being tested for the first time in the delivery room
had higher prevalence of HBsAg(+) compare to those with
documented prenatal care (4.2% versus 2.3%, p = 0.10)
Table (2). Many of the women of Greek origin not tested
prenatally however, reported past HBsAg(-) testing during
a previous pregnancy. Although overall HBsAg carriage
did not correlate with maternal age, we found that among
women tested during prenatal care, seropositive women
were slightly younger Table (3).
One hundred twenty-two women (3.2%) were never
tested (prenatally, perinatally, or during previous preg-
nancy). Most of them delivered in public clinics (77.6%
versus 22.4% women, p < 0.001). Moreover not being
ever tested for HBsAg correlated with maternal education;
16/72 (22.2%) of women never tested reported illiteracy
compare to 50/2907 (1.7%) in the total population (p <
0.001). We found no association with ethnicity or mater-
nal age. However, it is worth noticing that among those
women not tested prenatally or perinatally, women of
Greek origin were less likely to be primiparous compare to
immigrant women (11,4% of Greek and 27,8% of immi-
grant women respectively p = 0.002). Finally, no geo-
graphic region was found to have a significantly higher
Table 1: Study population, prevalence of HBsAg(+) and prenatal screening for HBsAg by origin.
ORIGIN No (%) Prevalence of HBsAg(+)** Prenatal screening for HBsAg
GREEK 3007 (79.97%) 46/2705(1.7%)*** 2467/2641(93.4%)***
ALBANIAN 409 (10.88%) 36/368(9.8%) 227/288 (78.8%)
IMMIGRANT* 258 (6.86%) 13/228(5.7%) 104/119 (87.4%)
GIPSY 86 (2.28%) 3/83(3.6%) 31/43 (72.1%)
TOTAL 3760 98/3384(2.89%) 2856/3128 (91.3%)
* other than Albanian
** Total prevalence in women tested either prenatally or perinatally
*** Statistically significant difference among Greek women versus non-Greek in HBsAg (+) prevalence and in prenatal screening was p < 0.001.
Table 2: HBsAg(+) prevalence by origin and time of 1st documented screening for HBV.
Origin Prenatal Delivery room
Greek 34/2467 (1.4%) 3/174 (1.7%)
Albanian 20/227 (8.8%) 6/61 (9.8%)
Others* 11/135 (8.1%) 2/27 (7.4%)
Total 65/2829 (2.3%)** 11/262 (4.2%)**
*Others = non-Greek/non-Albanian women
** p = 0.10BMC Infectious Diseases 2006, 6:84 http://www.biomedcentral.com/1471-2334/6/84
Page 4 of 6
(page number not for citation purposes)
prevalence of HBsAg or a lower percentage of screening
pregnant women.
According to medical charts, in all identified cases of an
HBsAg(+) mother, appropriate passive and active immu-
noprophylaxis was given within 24 hours. In one case a
newborn of a HBsAg(-) woman was inadvertently given
active and passive immunoprophylaxis.
Discussion
Since selective screening of high risk pregnant women for
HBsAg has failed to identify a significant proportion of
HBV-infected mothers [2,18-20], prenatal HBsAg testing
of all pregnant women has been recommended [2]. Uni-
versal prenatal testing would identify annually in the USA
alone, an estimated 22,000 HBsAg (+) women and could
prevent at least 6,000 chronic HBV infections in their off-
springs [21].
The aim of the study was to evaluate the compliance of all
Obstetric clinics with National Guidelines for the preven-
tion of perinatal HBV infection with universal screening
for HBsAg in pregnant women and the application of
immunoprophylaxis in newborns to HBV carrier women.
An excellent cooperation from all the obstetric clinics was
observed. The number of deliveries during the study
period, is in accordance with the annual birth rate
reported (National Census 2001) as well as the number of
Gurthrie cards completed over the study period and sent
to the National Institute of Child Health. Furthermore,
the demographics of women such as ethnicity percent-
ages, correlated with those from our last National Census
of 2001.
The overall prevalence of HBsAg (+) in pregnant women
was 2.89%. Our result is in accordance with an earlier
study in a Maternity Hospital in Athens [22]. The preva-
lence of HBsAg (+) was significantly lower among Greek
women (1.7%) compare to non-Greek women. Especially
high prevalence was found in women born in Albania
(9.8%). As shown in previous epidemiologic studies in
Greece, HBsAg-seropositivity is more prevalent in immi-
grant women compare to women of Greek origin [23,24].
Previously, Malamitsi-Puchner et al., found that immi-
grant women from Albania had HBsAg (+) prevalence of
13.4% [23] whereas another study in the early 1990's
from Ioannina, a town in the border with Albania, exam-
ined the seroprevalence of HBV markers in refugees from
Albania and showed an overall carrier rate of 22.2% with
higher prevalence rates in younger immigrants [24]. In
this study however, almost two thirds of the study popu-
lation involved men. The authors suggest that low socioe-
conomic status and poor hygiene are important factors for
horizontal transmission in this group. It is therefore pos-
sible that the lower prevalence found in our study com-
pare to previous studies is due to the improvement of the
socioeconomic status of immigrants. No geographical
region showed significantly increased prevalence of
HBsAg(+). Studies from other European countries show a
decreased prevalence of chronic HBV-infection among
pregnant women (1.0 –1.7%) compare to women deliver-
ing in Greece [25-27].
The overall incidence of prenatal screening was 91.3%,
significantly higher that that documented in previous
studies where only 63.1% had documentation of prenatal
HBsAg testing and 10.3% had never had any prenatal
examination [22]. In a recent Italian study, however,
91.8% of women had had prenatal screening for HBV-
infection [25].
Greek women were more likely to have had prenatal
screening for HBV infection Table (1). Women with no
documented prenatal screening for HBsAg were more
likely to be HBV chronically-infected (4.2% versus 2.3%,
p = 0.10). This was true for Greek and Albanian women
only. One could postulate that due to language barrier,
the percentage of prenatal screening in non-Greek/non-
Albanian women was underestimated since HBsAg-serop-
ositivity was lower in this group of women tested for the
first time in the delivery room Table (2).
As shown in a previous study [22], younger maternal age
was an identifiable risk factor for HBsAg(+) in the sub-
group of women with documented prenatal screening.
It is quite disturbing that during the two weeks of this
study, while there was high awareness on HBV vertical
transmission and therefore more women than usual
might have been tested, 3.2% of women in our study had
no documentation of prenatal or perinatal HBsAg screen-
ing. Risk factors identified included delivering in a Public
Hospital and maternal illiteracy. Although deliveries were
evenly distributed between public and private clinics
Table 3: Maternal mean age in years (+/- SD) by HBsAg serostatus
HBsAg (+) HBsAg (-) P value
Prenatal screening 28.69 (6.8) 29.5 (5.0) P = 0.05
Delivery room 29.2 (6.3) 29.7 (4.8) NS
Total 28.7 (6.6) 29.3 (5.1) NSBMC Infectious Diseases 2006, 6:84 http://www.biomedcentral.com/1471-2334/6/84
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(46.7% and 53.3% respectively), we found that more than
2/3 of women never tested delivered in a public hospital.
Interestingly, in a recent Italian study women delivering in
a Private Maternity Hospital were more likely not
screened for HBV infection during pregnancy [25]. Mater-
nal age, ethnicity and geographic region did not show any
association with not ever being tested for HBsAg.
Conclusion
Although the prevalence of HBsAg in Greek pregnant
women is low and comparable to other European coun-
tries, immigrant women living in Greece which compose
almost 20% of our childbearing population have signifi-
cant higher prevalence rates. There has been significant
improvement in the adherence to the antenatal screening
guidelines over the past decade but, according to our
results, there are still women who never get tested. Univer-
sal vaccination against HBV at birth and perinatal testing
of all, not tested prenatally, women should be discussed
with Public Authorities. The identification of HBsAg (+)
mothers, even postnatally, is necessary for the administra-
tion of HBIG and most importantly for the appropriate
follow up of these infants to ensure completion of vacci-
nation against HBV and serologic testing according to
guidelines.
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